Bloomberg: Buried Complaints Left a Damaging Cancer Device on the Market

October 13, 2025

For a patient, especially one navigating the difficult journey of breast cancer treatment, trust is paramount. Trust in their doctors, trust in the treatments recommended, and trust in the medical devices designed to aid their recovery. When that trust is broken, the consequences can be devastating, leaving not just physical scars, but deep emotional and financial wounds. At Jason Joy & Associates, we believe that no one should suffer in silence due to the negligence of others. Our firm is dedicated to fighting for victims of personal injury, ensuring their voices are heard and that they receive the justice and compensation they deserve.

A recent investigation has brought to light a story of corporate negligence that is both shocking and deeply concerning for thousands of breast cancer survivors. A medical device, intended to help, has allegedly caused immense suffering, with complaints being hidden from the public and regulatory bodies for years.


In a powerful piece for Bloomberg, author Anna Edney revealed the distressing story of the BioZorb implant:


"The plastic implant is just a few centimeters long. It’s hard to fathom that it could create such torment, but hundreds of women say the device, called BioZorb, caused them excruciating pain, infections that wouldn’t heal and resulted in deformed breasts despite claims otherwise.


The US Food and Drug Administration approved BioZorb in 2012 as a radiographic marker for use after breast cancer surgery. Its plastic part was supposed to dissolve and leave behind tiny pieces of titanium that would show up on imaging machines to mark where a tumor had been removed. The two companies that sold BioZorb pushed it as something more — a device that would provide scaffolding for women’s breast tissue to grow back in a more aesthetically pleasing way before the plastic dissolved.


Except in many cases the plastic didn’t dissolve. And the companies kept breast cancer survivors’ complaints from the FDA and the public, some for as long as a decade. I was able to figure this out with my colleague Tanaz Meghjani, a data expert. She helped me analyze an FDA database of complaints about medical devices, which Hologic Inc., BioZorb’s most recent and last maker, only recently began updating after lawsuits were filed."


Legal Insights from Jason Joy & Associates


The story uncovered by Bloomberg is not just an isolated incident; it points to a potential systemic failure that has affected hundreds, if not thousands, of patients who put their faith in a medical product during one of the most vulnerable times of their lives. From our perspective as a firm specializing in mass torts and dangerous product litigation, this story carries significant weight for several reasons.


First, the credibility is bolstered by the sheer volume of similar complaints from women across the country. In mass tort litigation, a pattern of similar injuries linked to a single product is a powerful indicator that a defect or failure to warn is not an anomaly, but a widespread problem. The reports of pain, infection, device migration, and the failure of the plastic component to dissolve suggest a fundamental issue with the BioZorb device.


Second, the allegation that the manufacturers were aware of these complaints and failed to report them to the FDA is a serious breach of trust and legal duty. Medical device companies have a responsibility to monitor the performance of their products and report adverse events. Hiding this information not only prevents the public and the medical community from making informed decisions but also allows a potentially dangerous product to remain on the market, harming more patients. This is a classic example of corporate negligence where profits may have been prioritized over patient safety.


This story deserves wider attention precisely because of the number of patients affected and the vulnerable position they were in. Breast cancer survivors undergo physically and emotionally taxing treatments. To then face complications, pain, and the need for additional surgeries from a device that was supposed to aid in their recovery is a profound injustice.


How We Can Help: Compassionate Advocacy on Your Side


At Jason J. Joy & Associates, we are actively supporting victims of BioZorb complications. We understand that coming forward can be an incredibly difficult step. Many survivors of traumatic medical experiences feel overwhelmed, and the thought of a legal battle can seem daunting. Our approach is founded on compassion and understanding. We are here to listen to your story, validate your experience, and provide clear, straightforward legal guidance. Our team, based in Houston and licensed to practice in both Texas and Louisiana, is committed to creating a safe and supportive environment for our clients.


We have a proven track record of standing up to large corporations and holding them accountable for the harm they cause. We know the tactics these companies use to minimize their responsibility, and we have the experience and resources to counter them effectively.


You Don't Pay Unless We Win


One of the greatest barriers that prevents victims from seeking justice is the fear of cost. We want to eliminate that worry completely. Jason Joy & Associates operates on a contingency fee basis. This means you will not be charged any upfront fees for our services. We invest our own resources into building and fighting your case. We only get paid if you get paid through a settlement or a verdict in your favor. If we don't win your case, you owe us nothing. This approach allows you to access top-tier legal representation without any financial risk, enabling you to focus on what truly matters: your health and well-being.


Your Story Deserves to Be Heard


If you or a loved one has suffered from complications after the implantation of a BioZorb device—such as chronic pain, infection, device migration, or the need for additional surgeries—please do not suffer in silence. The time to act is now.


The team at Jason J. Joy & Associates is ready to hear your story and provide the legal guidance you need to move forward. Contact our Houston, Texas office today for a free, no-obligation consultation. Let us stand with you and fight for the justice you deserve.

Contact Us

By submitting this form you agree to receive text messages.

By Rebecca Rivera December 9, 2025
As reported in the Washington Post December 5th, 2025 by Amudalat Ajasa A prominent scientific journal, Regulatory Toxicology and Pharmacology, has retracted a widely cited 2000 study that previously concluded the active ingredient in Roundup, glyphosate, posed no cancer risk to humans. The retraction was initiated after evidence emerged suggesting the study was heavily influenced by the herbicide's seller, Monsanto (now owned by Bayer), in an apparent effort to disguise potential health risks. Specific concerns cited by the journal include the strong possibility that Monsanto employees contributed to the writing without proper acknowledgment, that the authors may have received undisclosed payments from the company , and that the findings were based solely on unpublished Monsanto studies. This misconduct, discovered through internal company emails during federal litigation, is significant because the faulty research served as a bedrock for regulatory decisions regarding glyphosate for decades. Summary of Alleged Faulty Study and Monsanto's Influence The Study and Its Conclusion: The retracted paper, published in 2000, was a "bedrock study" that concluded: "under present and expected conditions of new use, there is no potential for Roundup herbicide to pose a health risk to humans." The Retraction: The scientific journal retracted the study due to a loss of confidence in its results and conclusions, citing the need to "maintain the integrity of the journal." Evidence of Undisclosed Influence: The co-editor in chief cited evidence suggesting that Monsanto employees "may have contributed to the writing of the article without proper acknowledgment as co authors." Undisclosed Payments: The retraction also noted that the study's authors may have been paid by Monsanto without disclosing it . Basis of Findings: The journal stated that the study's findings about cancer risk were "solely based on unpublished studies from Monsanto." Discovery of Influence: Monsanto's influence over the study was reportedly discovered through internal emails released during federal litigation against the company in 2017. Impact: The study "had a significant impact on regulatory decision-making regarding glyphosate and Roundup for decades," and was one of the most-cited papers on glyphosate safety, underpinning federal regulations for the pesticide. The Environmental Protection Agency (EPA) even cited it in its 2016 review of glyphosate. Context and Aftermath Bayer's Defense: Bayer (which acquired Monsanto in 2018) defended the chemical's safety and argued that Monsanto's involvement was appropriately cited in the acknowledgments, stating that glyphosate is the most extensively studied herbicide and that the "vast majority of published studies on glyphosate had no Monsanto involvement." Regulatory Stance: The EPA stated the retraction would not affect its current stance —which is that glyphosate is "not likely to be carcinogenic to humans"—because the agency does not directly rely on review articles like this one, but uses them to find other relevant individual studies. Litigation: Bayer has spent approximately $10 billion to settle lawsuits arguing the company did not warn customers about the negative health impacts of using Roundup. Read the full article in the Washington Post
By Rebecca Rivera November 14, 2025
In this series premiere episode, Founder & President of SOSCSA, Child Sexual Abuse Survivor & BSA Bankruptcy Claimant, Curtis Garrison interviews attorney Jason J Joy for an update on the BSA bankruptcy and discussing childhood abuse litigation for which Jason is an outspoken and experienced advocate. Jason's firm is actively litigating cases for many clients his law firm represents. This podcast is recommended for clients already represented, and for those who are still contemplating coming forward to establish a claim. Topics covered in this episode: Recent BSA Bankruptcy Trust report Lajun Claimants (Guam) v. Boy Scouts of America and their recent Petition For A Writ Of Certiorari to the U.S. Supreme Court The 1.5% initial payment, possible second payment time / total percentage Future Claims, BSA Councils, BSA Charters (churches, schools, etc) which there are over 100,000 entities possibly getting free of liability Mixed Claims explained We did not vote for this plan, they promised we would be paid in “Paid in Full” Plans to file an Amicus Brief Statute of Limitations 
By Rebecca Rivera November 6, 2025
The Boy Scouts of America bankruptcy case, involving tens of thousands of survivors of childhood sexual abuse, is among the largest and most contentious mass tort proceedings in U.S. history. In this podcast, Attorney Jason Joy breaks down the latest ruling from the Third Circuit Court, which leaves many survivors of childhood sexual abuse with drastically underfunded compensation.